ID   MM-A1
AC   CVCL_M536
DR   Wikidata; Q54906013
RX   DOI=10.1007/0-306-46877-8_4;
RX   PubMed=2072743;
RX   PubMed=10936422;
CC   Population: Japanese.
CC   Characteristics: Produces IgG lambda.
CC   Characteristics: IL6 dependent.
CC   Doubling time: 48 hours (PubMed=2072743).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   39Y
CA   Cancer cell line
DT   Created: 05-11-13; Last updated: 29-06-23; Version: 13
//
RX   DOI=10.1007/0-306-46877-8_4;
RA   Jernberg-Wiklund H., Nilsson K.;
RT   "Multiple myeloma cell lines.";
RL   (In) Human cell culture. Vol. 3. Cancer cell lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York (2000).
//
RX   PubMed=2072743;
RA   Okuno Y., Takahashi T., Suzuki A., Ichiba S., Nakamura K.,
RA   Fukumoto M., Okada T., Okada H., Imura H.;
RT   "Establishment and characterization of four myeloma cell lines which
RT   are responsive to interleukin-6 for their growth.";
RL   Leukemia 5:585-591(1991).
//
RX   PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   multiple myeloma and plasma cell leukemia.";
RL   Leuk. Res. 24:681-703(2000).
//